Trial Profile
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Retifanlimab (Primary)
- Indications Cervical cancer; Endometrial cancer; Non-small cell lung cancer; Sarcoma; Solid tumours
- Focus Adverse reactions
- Acronyms POD1UM-101
- Sponsors Incyte Corporation; MacroGenics
- 24 Oct 2023 Final results from the POD1UM-101 study (Cohort H, n=76) presented at the 48th European Society for Medical Oncology Congress.
- 16 Oct 2023 According to Incyte media release, final results from this study will be presented t the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid.
- 09 Nov 2022 Planned End Date changed from 27 Feb 2024 to 27 Apr 2024.